Fractyl Health reports Revita sustains weight loss after GLP-1 therapy ends

Fractyl Health has released data from its REMAIN-1 Midpoint Cohort showing that patients treated with its investigational procedure, Revita®, continued to lose weight three months after stopping GLP-1 therapy, according to the company. In the randomized, double-blind, sham-controlled study (N = 45),…